Merck Challenges Safety & Validity of All Ivermectin Studies for COVID-19, Despite Having Donated Billions of Doses to Less-Developed World to Fight Parasites & Accumulating Positive Data

A February 4 press release from Merck is raising yet more questions about why research money is not going to ivermectin and why this seemingly effective drug is so underutilized, even in North American research. In the statement Merck, one of America’s great pharmaceutical companies and manufacturer of the Stromectol/Mectizan branded versions of ivermectin, claims that: 1) there is no evidence that ivermectin works for COVID-19, and 2) there is a “concerning lack of safety data in the majority of studies,” suggesting that the drug may be unsafe. Concern two is odd, given that Merck has proudly donated billions of doses of ivermectin to fight river blindness. On its website, Merck boasts that its own Dr. William Campbell first suggested the use of ivermectin for river blindness in the late 1970s and that from 1987 to today Merck has committed to donating, “as much as needed, for as long as needed” to eliminate river blindness. The firm notes that the ivermectin program, “reaches more than 300 million people in the affected areas annually, with more than 4 billion treatments donated since 1987.” And according to the August 2020 version of NIH’s COVID-19 Treatment Guidelines, ivermec...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee